Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Elena Del Alcázar-ViladomiuJ A Suárez-PérezS ArmestoR RiveraE Herrera-AcostaP HerranzI MartínE MontesinosM HospitalE VilarrasaM FerranRicardo Ruiz VillaverdeAntonio Sahuquillo-TorralbaDiana P Ruiz GenaoS Pérez-BarrioC MuñozM LlamasF ValentíM J MitxelenaA López-FerrerG CarreteroD VidalJ MolletI BelinchónJ M CarrascosaPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Apremilast may be a suitable alternative for the treatment of moderate to severe psoriasis and palmoplantar psoriasis. Although the drug has a good safety profile, adverse gastrointestinal effects are common.